![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Teva will use Closed Loop Medicine’s proprietary SaMD platform which advances the development of personalised medicines, including CLM-HT01 (amlodipine), in patients with chronic disorders by combining dose-optimised drug therapy with digital care.
Lead Product(s): Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CLM-HT01
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 26, 2024
Details:
Under the partnership, Closed Loop’s proprietary Software-as-a-Medical Device dosing optimization technology will be combined with Pharmanovia’s established anti-hypertensive medicines to develop drug + software product solutions for the treatment of hypertension.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pharmanovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 17, 2023